drugset / Trial / NCT06414473

CBD for Knee Osteoarthritis

NCT06414473

Phase 1/2 Recruiting 30 enrolled University of Florida
RandomizedCrossoverTriple-blindTreatment

Summary

Osteoarthritis is a disease that affects millions of Americans and is the leading cause of persistent pain and physical disability in the older adult population. Many physically active Americans have reported pain-relieving effects of cannabidiol (CBD) that can reduce or eliminate use of nonsteroidal anti-inflammatory drugs (NSAIDs) for activity-related pain with minimal to no side effects. Long-term use of over-the-counter medications, including NSAIDs, can pose a significant health risk, and therefore clinical research on the safety and efficacy of CBD is needed.

Timeline

Start
2024-06-14
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified Subcutaneous

Indications